Kidney Cancer Clinical Trial

Clinical Trial Finder Kidney Cancer Trials

A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)

See Locations Near You

Summary

This clinical study is being conducted at multiple sites to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in papillary renal cell carcinoma. Papillary renal cell carcinoma may be classified into hereditary and sporadic forms; subjects with either classification will be accepted into this study.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histologically confirmed diagnosis of PRC with metastatic disease or bilateral multifocal renal tumors localized to kidneys. Measurable disease, ECOG performance status of Adequate bone marrow reserve, hepatic, renal, and cardiovascular function.

Exclusion Criteria:

Radiation to >/=25% of bone marrow within 14 days of GSK1363089, more than 1 prior anti-cancer therapy, received prior treatment with a c-met inhibitor, brain metastases,
Any uncontrolled intercurrent illness,
Pregnant or breastfeeding,
HIV positive

Study is for people with:

Kidney Cancer

Phase:

Phase 2

Estimated Enrollment:

74

Study ID:

NCT00726323

Recruitment Status:

Completed

Sponsor:

GlaxoSmithKline

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 12 Locations for this study

See Locations Near You

GSK Investigational Site
Greenbrae California, 94904, United States
GSK Investigational Site
San Francisco California, 94115, United States
GSK Investigational Site
Stanford California, 94305, United States
GSK Investigational Site
Indianapolis Indiana, 46202, United States
GSK Investigational Site
Bethesda Maryland, 20892, United States
GSK Investigational Site
Boston Massachusetts, 02115, United States
GSK Investigational Site
Detroit Michigan, 48201, United States
GSK Investigational Site
New Brunswick New Jersey, 08901, United States
GSK Investigational Site
Cleveland Ohio, 44195, United States
GSK Investigational Site
Philadelphia Pennsylvania, 19104, United States
GSK Investigational Site
Nashville Tennessee, 37232, United States
GSK Investigational Site
San Antonio Texas, 78229, United States
Load More

How clear is this clinincal trial information?

Study is for people with:

Kidney Cancer

Phase:

Phase 2

Estimated Enrollment:

74

Study ID:

NCT00726323

Recruitment Status:

Completed

Sponsor:


GlaxoSmithKline

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider